Risk Of Developing Liver Cancer After HCV Treatment

▼
Showing posts with label IDX719. Show all posts
Showing posts with label IDX719. Show all posts
Thursday, April 25, 2013

EASL: Idenix Reports Favorable Resistance Profile for IDX719

›
Idenix Reports Favorable Resistance Profile for IDX719, a Potent, Pan-Genotypic HCV NS5A Inhibitor, at EASL Meeting CAMBRIDGE, Mass., Apr...
Monday, April 8, 2013

EASL-Idenix will present data on IDX719

›
Idenix Announces Data Presentation at the 48th Annual Meeting of the European Association for the Study of the Liver (EASL) CAMBRIDGE, Mass...
Tuesday, January 29, 2013

Janssen and Idenix - The Newest Hep-C Partnership

›
Investment Commentary Source - The Motley Fool A collaboration between Janssen and Idenix is the highlight of this video. The collabora...
Saturday, November 10, 2012

AASLD- Idenix Reports On IDX719 and IDX184

›
Idenix Pharmaceuticals Reports Clinical Data for HCV Drug Candidates - IDX719 and IDX184 - at the American Association for the Study of Live...
Thursday, November 1, 2012

Idenix Reports Financial Results and HCV Program Update

›
Idenix Pharmaceuticals Reports Third Quarter and Nine Month 2012 Financial Results and HCV Program Update CAMBRIDGE, Mass., Nov. 1, 2012 ...
Wednesday, July 25, 2012

IDX719-Idenix hepatitis C drug Receives Fast Track Designation

›
July 25, 2012   IDX719 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C Infection CAMBRIDGE, Mass....
Tuesday, July 3, 2012

Idenix: New HCV Drug Could Be A Blockbuster

›
Idenix: New HCV Drug Could Be A Blockbuster Cris Frangold Seeking Alpha Idenix Pharmaceuticals, Inc. ( IDIX ) recently announced e...
Tuesday, June 19, 2012

HCV Drug Candidates IDX184 and IDX719-Idenix Announces Positive Clinical Data

›
Idenix hep C drug shows promise in mid-stage study (Reuters) Idenix Pharmaceuticals Inc said interim data from a mid-stage trial on its ...
Thursday, April 19, 2012

Idenix Pharmaceuticals Provides Update on Hepatitis C Clinical Development Programs

›
April 19, 2012 Idenix Pharmaceuticals Provides Update on Hepatitis C Clinical Development Programs IDX719 Demonstrates Pan-Genotypic Act...